Subscribe to RSS
Synthesis of PSI-352938
P. G. Reddy, B.-K. Chun, H.-R. Zhang, S. Rachakonda, B. S. Ross*, M. J. Sofia
Pharmasset, Inc., Princeton, USA
20 July 2011 (online)
PSI-352938 is an orally active, nucleotide prodrug that inhibits HCV NS5B polymerase. It is currently in clinical trials for the treatment of hepatitis C. Noteworthy features include broad genotype coverage and a good resistance profile. The synthesis depicted delivered multikilogram quantities of API without recourse to chromatography.